Last updated: 2026-09-09 10:17:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Wave Life Sciences Ltd. (WVE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4,95, with a market capitalisation of $957,65M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,65 to $21,73. This page covers its latest market performance, valuation, price trends and company information.
$957,65M | |
$4,88 | |
$56,00 | |
$1,16 | |
$4,91 | |
1,00 | |
3,13M | |
-- | |
$21,73 | |
$4,64 | |
-- | |
-- |
Wave Life Sciences Ltd. (WVE) is trading at $4,95 in pre-market trading as of 2026-09-09 08:02:00, up 0,81% ($0,04) from the previous close of $4,91
Pre-market trading shows how investors are pricing WVE before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Wave Life Sciences Ltd. (WVE) moved from $5,04 to $4,95, representing a decline of 1,79% ($0,09).
The stock traded between $4,65 and $5,22 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 3,90 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1,8%
WVE is currently trading at $4,95, placing it 1,8% of the way from its 52-week low of $4,65 to its 52-week high of $21,73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 317 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Wave Life Sciences Ltd. (WVE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.